<DOC>
	<DOC>NCT00467896</DOC>
	<brief_summary>A Comparison of Safety and Inhalation Times of Ventavis (iloprost) Inhalation Solution delivered by I-Neb Utilizing Power Disc-6 and Power Disc-15 "Power 15 Study"</brief_summary>
	<brief_title>The "Power 15 Study": Safety Study of Inhalation of Ventavis With the Power Disc-15 Setting</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertension, Pulmonary</mesh_term>
	<mesh_term>Iloprost</mesh_term>
	<criteria>Male or female, aged 1885 years Have a current diagnosis of symptomatic pulmonary arterial hypertension (PAH) classified by one of the following: a) idiopathic pulmonary arterial hypertension (IPAH) or familial pulmonary arterial hypertension (FPAH); b) PAH associated with one of the following connective tissue diseases and mild or no lung parenchymal disease: scleroderma spectrum of disease, systemic lupus erythematosis, or mixed connective tissue disease, c) PAH associated with repaired atrial septal defect (ASD), ventricular septal defect (VSD), or patent ductus arteriosis (PDA) ≥ 1 year postoperative from Screening, d) PAH associated with human immunodeficiency virus (HIV), or e) PAH associated with the use of anorexigens (e.g. fenfluraminephentermine) On a stable and well tolerated dose regimen of Ventavis (5 μg per dose) for at least 4 weeks prior to the Screening visit, using the Ineb AAD System equipped with Power Disc6 Receipt of any prostacyclin or prostacyclin analogue other than Ventavis within the 12 weeks preceding the Screening visit Receipt of atrial septostomy within the 6 months preceding Screening History of leftsided heart disease Clinically relevant obstructive lung disease Chronic renal or liver disease Uncontrolled systemic hypertension or hypotension Cerebrovascular event within the 6 months preceding Screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>PAH</keyword>
	<keyword>iloprost</keyword>
	<keyword>Ventavis</keyword>
	<keyword>Pulmonary Arterial Hypertension</keyword>
	<keyword>Actelion Pharmaceuticals</keyword>
	<keyword>Cotherix</keyword>
</DOC>